New drug combo aims to keep viral pneumonia patients out of hospital

NCT ID NCT06202521

First seen Jan 11, 2026 · Last updated May 15, 2026 · Updated 16 times

Summary

This study tested whether adding the drug silmitasertib to standard care helps adults with viral pneumonia (from COVID-19 or flu) avoid hospitalization or death. About 45 outpatients with mild-to-moderate pneumonia took part. The trial was stopped early, so results are limited.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COMMUNITY-ACQUIRED PNEUMONIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Far Eastern Memorial Hospital

    New Taipei City, Taiwan

  • Kaohsiung Veterans General Hospital

    Kaohsiung City, Taiwan

  • National Taiwan University Cancer Center, National Taiwan University Hospital

    Taipei, Taiwan

  • National Taiwan University Hospital

    Taipei, Taiwan

  • Taichung Veterans General Hospital

    Taichung, Taiwan

  • Taoyuan General Hospital, Ministry of Health and Welfare

    Taoyuan, Taiwan

  • Tri-Service General Hospital

    Taipei, Taiwan

Conditions

Explore the condition pages connected to this study.